SCHEMBL4075180

SCHEMBL4075180

Fc1cnc(Cl)nc1-c1cc2ccccc2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCK P27707 2/20 0.43
APP P05067 2/20 0.40
ERN1 O75460 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
PRKDC P78527 1/20 0.39
CYP19A1 P11511 1/20 0.39
KDM1A O60341 1/20 0.39
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
PGK1 P00558 1/20 0.37
MAPT P10636 1/20 0.37
IKBKB O14920 1/20 0.36
PLAU P00749 1/20 0.36
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3965523 0.85 APP (0.41) APPPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3963838 0.82 PIK3CD (0.41) APPPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2975949 0.82 PIK3CA (0.41) APPPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2980726 0.82 PDE3B (0.38) DCKAPPERN1PIK3CDPIK3CA
SCHEMBL394534 0.79 ABL1 (0.34) MAPT
SCHEMBL3965727 0.76 KDM4E (0.34) CA1CA2CA9
SCHEMBL2977608 0.76 TRPM5 (0.33)
SCHEMBL2923179 0.74 TDO2 (0.39) ADORA2AADORA1
SCHEMBL7253693 0.73 CYP2A6 (0.42) KDM1AMAPT
SCHEMBL594142 0.72 CA12 (0.30) CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG DCK 787/4885APP 645/4885ERN1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.